Viatris VTRS Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

McKessonMCK

$292M-1.7%

AMP

Amphastar PharmaceuticalsAMPH

$8.8M+11.7%

Aquestive Therapeutics, Inc.AQST

$820K+43.9%

Amneal Pharmaceuticals, Inc.AMRX

$58.8M+25.0%

Scilex Holding CompanySCLX

$1.72M+133%

BridgeBio PharmaBBIO

$3.32M-30.7%

FAQ

What is Viatris's operating lease liabilities (current)?

Viatris (VTRS) reported operating lease liabilities (current) of $115.3M in Q2 2026.

How has Viatris's operating lease liabilities (current) changed year-over-year?

Viatris's operating lease liabilities (current) increased by 3.3% year-over-year, from $111.6M to $115.3M.

What is the long-term trend for Viatris's operating lease liabilities (current)?

Over 5 years (2020 to 2025), Viatris's operating lease liabilities (current) has grown at a 3.3% compound annual growth rate (CAGR), from $92.9M to $109.4M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.